JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M202410200 on April 5, 2002

J. Biol. Chem., Vol. 277, Issue 24, 21768-21775, June 14, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/24/21768    most recent
M202410200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaille, C.
Right arrow Articles by Haas, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaille, C.
Right arrow Articles by Haas, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Salicylate Biosynthesis in Pseudomonas aeruginosa

PURIFICATION AND CHARACTERIZATION OF PchB, A NOVEL BIFUNCTIONAL ENZYME DISPLAYING ISOCHORISMATE PYRUVATE-LYASE AND CHORISMATE MUTASE ACTIVITIES*

Catherine GailleDagger , Peter Kast§, and Dieter HaasDagger

From the Dagger  Laboratoire de Biologie Microbienne, Université de Lausanne, CH-1015 Lausanne and the § Laboratorium für Organische Chemie, Swiss Federal Institute of Technology, CH-8093 Zürich, Switzerland

Received for publication, March 12, 2002, and in revised form, April 3, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isochorismate pyruvate-lyase (IPL), the second enzyme of pyochelin biosynthesis and the product of the pchB gene, was purified to homogeneity from Pseudomonas aeruginosa. In the reaction catalyzed by this enzyme, isochorismate right-arrow salicylate + pyruvate, no cofactors appear to be required. At the pH optimum (pH 6.8), the enzyme displayed Michaelis-Menten kinetics, with an apparent Km of 12.5 µM for isochorismate and a kcat of 106 min-1, calculated per monomer. The native enzyme behaved as a homodimer, as judged by molecular sieving chromatography, electrophoresis under nondenaturing conditions, and cross-linking experiments. PchB has approximately 20% amino acid sequence identity with AroQ-class chorismate mutases (CMs). Chorismate was shown to be converted to prephenate by purified PchB in vitro, with an apparent Km of 150 µM and a kcat of 7.8 min-1. An oxabicyclic diacid transition state analog and well characterized inhibitor of CMs competitively inhibited both IPL and CM activities of PchB. Moreover, a CM-deficient Escherichia coli mutant, which is auxotrophic for phenylalanine and tyrosine, was functionally complemented by the cloned P. aeruginosa pchB gene for growth in minimal medium. A mutant form of PchB, in which isoleucine 88 was changed to threonine, had no detectable IPL activity, but retained wild-type CM activity. In conclusion, the 11.5-kDa subunit of PchB appears to contain a single active site involved in both IPL and CM activity.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Salicylate is a biosynthetic product and a precursor of secondary metabolites and siderophores (iron chelators) in several bacterial genera, e.g. Pseudomonas, Burkholderia, Azospirillum, Vibrio, Yersinia, and Mycobacterium (1-7). The first evidence for a bacterial salicylate biosynthetic pathway was obtained in Mycobacterium smegmatis, which incorporates shikimate into salicylate and the siderophore mycobactin derived from salicylate (8-10). Because isochorismate decomposes slowly into salicylate and 3-carboxylphenylpyruvate at pH 7 and room temperature, in the absence of enzymes, isochorismate was proposed to be the immediate precursor of salicylate (11). It was then shown that crude cell extracts of M. smegmatis convert chorismate and isochorismate to salicylate (Fig. 1), by the successive action of isochorismate synthase (ICS)1 and IPL (10, 12). Whereas ICS has been purified from Escherichia coli (13, 14), from Bacillus subtilis (15), and recently also from a plant (16), IPL has not yet been characterized as a pure enzyme from any organism.

In the ubiquitous bacterium and opportunistic human pathogen Pseudomonas aeruginosa, as in other organisms, chorismate is a precursor of aromatic amino acids, ubiquinone and folate (Fig. 1). In addition, phenazine compounds such as pyocyanin (17, 18) and the siderophore pyochelin (19) are produced by pathways branching off from chorismate (Fig. 1). Salicylate is a biosynthetic precursor of pyochelin in P. aeruginosa (1, 20). Genetic evidence indicates that the pchA and pchB genes encode ICS and IPL, respectively, in this bacterium (2). These genes are part of the pchDCBA operon, which, together with the pchEFGHI operon, code for the enzymes of the pyochelin pathway (21-24).

The deduced protein products of the P. aeruginosa pchB gene and its Pseudomonas fluorescens homolog pmsB both show approximately 20% sequence identity with CMs of the AroQ family (25-28); the significance of this low level similarity is unclear. CM catalyzes a Claisen rearrangement of chorismate, leading to prephenate, a common precursor in phenylalanine and tyrosine biosynthesis (Fig. 1).

P. aeruginosa has at least two CM activities (29-31). The first of these is due to the bifunctional P-protein (AroQ·PheA) consisting of a CM domain (AroQ) and a prephenate dehydratase domain, which produces phenylpyruvate, a phenylalanine precursor (Fig. 1). The second CM is a monofunctional, periplasmic enzyme (*AroQ).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Chorismate metabolism in P. aeruginosa. Biotransformations particularly relevant to this work are: 1, isochorismate synthase reaction (EC 5.4.99.6), catalyzed by PchA (2); 2, isochorismate pyruvate-lyase reaction (EC 4.1.99.-), catalyzed by PchB (2); 3, chorismate mutase reaction (EC 5.4.99.5), catalyzed by AroQ·PheA (bifunctional chorismate mutase-prephenate dehydratase), *AroQ (monofunctional periplasmic chorismate mutase) (29-31), and PchB (this study).

The aims of the present work are to characterize the properties of purified PchB from P. aeruginosa and to investigate its relationship to CM of the AroQ class.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- The endo-oxabicyclic diacid transition state analog inhibitor of CM and sodium isochorismate (used as a reference) were generous gifts from Drs. P. Bartlett (University of California, Berkeley, CA) and E. W. Leistner (University of Cologne, Cologne, Germany), respectively. Prephenic acid and phenylpyruvic acid were obtained from Sigma (Fluka Chemie AG, Switzerland). Carbenicillin was a gift from Glaxo-SmithKline. Chorismic acid was isolated from the CM-deficient Klebsiella pneumoniae strain 62-1 (ATCC 25306; Phe- Tyr- Trp-; Ref. 32), purified as the free acid according to the method of Grisostomi et al. (33) and stored at -80 °C. The purity of chorismic acid was 98% as determined by UV spectroscopy using epsilon 274 nm = 2,630 M-1 cm-1 (34) and 95.3% by analytical C-18 reverse phase HPLC at 280 nm. Prephenic acid, phenylpyruvic acid, and p-hydroxybenzoic acid were present at 0.6, 1.4, and 0.06%, respectively, as judged by HPLC. Isochorismate was isolated from K. pneumoniae 62-1 harboring the entC plasmid pKS3-02 (35), which was grown in medium A containing kanamycin (60 µg/ml), and transferred to 2-liter production medium BN (11) containing 0.1 mM each of tyrosine, phenylalanine, and tryptophan plus 0.3 mM isopropyl-beta -D-thio-galactopyranoside (IPTG) (35).

After precipitation with 2 M barium acetate, a 1:2 mixture of isochorismate and chorismate (600 mg from 2 liters of culture) was obtained, of which 50-mg portions were purified on a Nucleosil 120 C-18 column (10 × 250 mm) in aqueous 0.27% formic acid, pH 2.5. Elution at 4.1 ml/min was carried out by a methanol (%, v/v) step gradient: 10 min, 0%; 10-16 min, 0-19%; 16-41 min, 19%; 41-51 min, 19-28.5%; 51-58 min, 28.5%; 58-63 min, 28.5-95%; 63-73 min, 95% (35).2

Isochorismic acid and chorismic acid were eluted with 19% methanol after 30 min and with 28.5% methanol after 48 min, respectively, neutralized with NaOH, and freeze-dried. Isochorismate (epsilon 278 nm = 8,300 M-1 cm-1; Ref. 36) preparations adjusted to 200 µM contained 65 mM sodium formate, 43 µM sodium prephenate, and 20 µM sodium phenylpyruvate. No contamination of the isochorismate preparations with chorismate or with salicylate could be detected. At an isochorismate concentration giving half-maximal velocity (12.5 µM), the addition of 20 µM sodium prephenate, 8 µM sodium phenylpyruvate, or 26 mM sodium formate (i.e. a 10-fold excess over the contamination levels present in our isochorismate preparations) had no effect on IPL activity.

Isochorismate Determination by HPLC-- An analytical detection method at pH 7.0 was worked out for isochorismate, using a Nucleosil C-18 column (4 × 250 mm). Elution at a flow rate of 1 ml/min was carried out with a 0-65% (v/v) linear gradient of acetonitrile in 10 mM potassium phosphate buffer, pH 7.0, containing 5 mM ion pair reagent tetrabutylammonium hydrogen sulfate (Fluka), using a Hewlett-Packard 1050 system equipped with a diode array detector. p-Hydroxybenzoate (10.2 min), prephenate (10.9 min), chorismate (11.7 min), isochorismate (12.4 min), phenylpyruvate (15.6 min), and salicylate (16.4 min) were eluted at the retention times indicated and quantitated at lambda max with a diode array UV detector.

DNA Manipulation and Nucleotide Sequence Analyses-- Routine procedures were used for the isolation of DNA and for cloning experiments (37, 38). K. pneumoniae and E. coli strains were transformed with plasmid DNA by electroporation (39). Plasmid pME6152, containing pchB under the tac promoter, was constructed by cloning the 0.75-kb pchB XhoI-PstI fragment of pME3368 (2) in pMMB67EH (40). A 0.75-kb BamHI/HindIII fragment encoding pchB(I88T) from mutated pME6152 (see below) was subcloned into pUK21 (38) and pMMB67EH, resulting in pME6169 and pME6179, respectively.

The nucleotide sequence of the pchB(I88T) gene on pME6179 was determined by using the Thermo Sequenase II dye terminator cycle sequencing kit (Amersham Biosciences) and the ABI PrismTM 373 sequencer.

Purification of the PchB Enzyme-- P. aeruginosaADD1976/pME3324 (a T7 promoter expression vector with pchB; Ref. 2) was grown in 250 ml of nutrient yeast broth (2) containing carbenicillin (250 µg/ml) in 1-liter flasks with shaking at 37 °C. At A600 nm = 0.8, the chromosomal T7 RNA polymerase gene was induced for 1 h by the addition of IPTG at 1 mM final concentration. Rifampicin was then added at 200 µg/ml, and the incubation was continued for 2 h. All subsequent operations were carried out at 4 °C. Cells from three flasks were harvested by centrifugation at 8,000 × g for 10 min and washed twice in 50 mM potassium phosphate buffer (pH 7.5) containing 10% (v/v) glycerol and 1 mM dithiothreitol (DTT) (buffer A). Cells (wet weight of 3 g), which could be stored at -20 °C, were broken in 15 ml of buffer A by sonication for 5 × 30 s. Cell debris was removed by centrifugation at 10,000 × g for 30 min; the resulting crude extract containing 8-10 mg/ml protein was applied to a 1.6 × 20-cm DEAE-Sepharose CL-6B column (Amersham Biosciences) equilibrated with buffer A. The enzyme was eluted with 300 ml of buffer A at a flow rate of 1 ml/min. The fractions containing PchB, detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 10-20% gradient gels stained with Coomassie Blue, were combined (100 ml) and loaded onto a column of phenyl-Sepharose CL-4B (1.6 × 10 cm) previously equilibrated with 200 ml of buffer A. The enzyme was eluted as a broad peak with 150 ml of buffer A. Fractions containing PchB were pooled (80 ml), and a solution of 0.4% (w/v) n-octyl-beta -glucopyranoside (Calbiochem) was slowly added by stirring to a final concentration of 0.1% (w/v), to avoid protein precipitation during the concentration steps.

This fraction was concentrated to 2 ml by ultrafiltration through an Amicon YM3 membrane in a stirred cell, followed by further concentration with an Amicon Centriplus C-10 concentrator (cut-off: 10,000 Da). The concentrated fraction was chromatographed on a 1.6 × 70-cm column of Bio-Gel P100 polyacrylamide gel (Bio-Rad) in buffer A at a flow rate of 6 ml/h. PchB-containing fractions were pooled, aliquoted, and stored at -80 °C. The protein concentration was determined by the method of Bradford (41) using a commercial reagent (Bio-Rad) and bovine serum albumin as the standard.

Molecular Mass Estimation and N-terminal Analysis-- The subunit molecular mass of PchB was estimated by SDS-PAGE (42) in 10-20% gradient gels (Ready Gel, Bio-Rad), with standards of the Low Molecular Weight Calibration Kit (Amersham Biosciences). The molecular mass of the native PchB was estimated by gel filtration chromatography on Sephadex G-150 (1.6 × 70 cm, 0.1 ml/min), Bio-Gel P100 (1.6 × 70 cm, 0.1 ml/min), and FPLC Superose 12 HR (10/30, 0.4 ml/min) columns in buffer A, with ribonuclease A (13.7 kDa), lysozyme (14.6 kDa), proteinase K (28.8 kDa), pepsin (34.5 kDa), protein A (42 kDa), ovalbumin (43 kDa), and bovine serum albumin (67 kDa) as markers. The elution volumes were plotted against the logarithm of molecular masses for the standards, and the linear regression curve was used to estimate the apparent molecular mass of PchB.

In addition, the molecular mass of native PchB was estimated from PAGE in nondenaturing gels of 7.5, 10, 12, 15, and 20% polyacrylamide, with the Low Molecular Weight Calibration Kit (Amersham Biosciences) as a standard, by Ferguson plot analysis (43). The slopes obtained from plots of the logarithm of relative mobility versus polyacrylamide concentration were plotted against the molecular weight of the standard proteins.

The N-terminal sequence of PchB was determined by Dr. P. James (ETH, Zürich, Switzerland) on an Applied Biosystems Peptide Sequencer model 473A, using the Edman degradation procedure.

Cross-linking of PchB-- Samples of 50 µl of purified PchB (0.54 µg/µl) in buffer A were treated with 3,3'-dithiobis(sulfosuccinimidylpropionate) (DTSSP) to a final concentration of 0.5 mM. The cross-linker was prepared immediately before use as a 5 mM solution in 50 mM potassium phosphate, pH 7.5, containing 0.75 M NaCl. The samples were incubated with constant agitation at room temperature for 30 min. The reaction was quenched by addition of 40 mM Tris-HCl buffer, pH 7.5. Each sample was split into two aliquots, treated with the solubilizing solution (final concentrations: 1.2% (w/v) SDS, 10% (w/v) sucrose, 10 mM Tris-HCl, pH 7.5) with or without 40 mM DTT to cleave the cross-links, incubated at 50 °C for 3 min, and subjected to SDS-PAGE on a 10-20% polyacrylamide gradient. Standard proteins (Low and High Molecular Weight Kits, Amersham Biosciences) and the PchB control were not exposed to DTSSP, but were otherwise treated in the same way.

Enzyme Assays-- IPL activity of PchB was determined by measuring the fluorescence of salicylate formed using an excitation wavelength of 305 nm and an emission wavelength of 440 nm in a PerkinElmer LS30 fluorimeter. Unless stated otherwise, the incubation mixture contained, in a final volume of 500 µl, 100 mM potassium phosphate buffer, pH 7.0, 600 µM isochorismate (purified by HPLC), 10% (v/v) glycerol, 10 mM MgCl2, 1 mM DTT, and enzyme. Controls without enzyme were included routinely, to correct for nonenzymatic reactions. The reaction at 37 °C was initiated by the addition of isochorismate and terminated by the addition of 10 µl of concentrated HCl, followed by extraction with 3 ml of ethyl acetate. Blanks were obtained from nonincubated reaction mixtures. The amount of salicylate formed was determined from a standard curve obtained with 0.5-8 µM salicylic acid (Fluka) in ethyl acetate. One IPL unit of enzyme activity is defined as the amount of enzyme converting 1 µmol of isochorismate to salicylate/min. The reaction was stopped within the first 10% of the isochorismate-to-salicylate conversion.

CM activity of PchB was assayed by the method of Cotton and Gibson (44) as modified by Ahmad and Jensen (45). The product of the enzymatic reaction, prephenate, is converted to phenylpyruvate under acidic conditions, which is subsequently measured by its absorbance at 320 nm at basic pH. The reaction mixture contained, in a final volume of 0.2 ml, 50 mM potassium phosphate, pH 7.0, 1 mM DTT, 1 mM chorismate, and enzyme. Control reaction mixtures lacking enzyme were always included to estimate the amount of prephenate formed nonenzymatically during the incubation period. Reactions were carried out at 37 °C and terminated by the addition of 0.1 ml of 1 M HCl, followed by incubation at 37 °C for 10 min to convert the prephenate formed to phenylpyruvate. Phenylpyruvate concentrations were determined at 320 nm after the addition of 0.7 ml of 2.5 M NaOH, using epsilon 320 nm = 17,500 M-1 cm-1 (44). One CM unit of enzyme activity is defined as the amount of enzyme needed for the formation of 1 µmol of prephenate (assayed as phenylpyruvate)/min.

Kinetic Studies-- Assays were performed in triplicate and repeated three times. Initial velocity data were fitted to the equations of Hanes (Table II), Lineweaver-Burk (Fig. 3, A-C), and Dixon using Enzpack software (Biosoft).

In Vivo CM Activity of PchB-- The CM-negative E. coli strain KA12 harboring pKIMP-UAUC (47, 48) with or without pME6152 (pchB+) was grown at 37 °C with shaking in 500-ml flasks containing 100 ml of minimal medium E (48), amended with 0.5% (w/v) glucose, 1 mM thiamine, and 1 mM IPTG. Control cultures were grown in minimal medium E supplemented with 1 mM tyrosine and 1 mM phenylalanine. The cultures were inoculated with approximately 107 washed cells/ml, previously grown in minimal medium E supplemented with both amino acids, ampicillin (100 µg/ml) and chloramphenicol (25 µg/ml). Cell growth was monitored by following the A600 nm.

Western Immunoblot Procedure-- Rabbit antibodies were generated by subcutaneous injection of purified PchB (110 µg/500 µl) emulsified with 500 µl of complete Freund's adjuvant. Three booster injections with the same amount of antigen at 4-week intervals were applied. Ten days after the final injection, blood was collected and aliquots of the serum obtained were kept at -80 °C. The enzyme (typically 0.1 µg) and cell extracts were subjected to SDS-PAGE and electrotransferred to a nitrocellulose sheet (Bio-Rad) in a Trans-Blot apparatus (Bio-Rad) with a transfer buffer containing 25 mM Tris base (pH 8.3), 192 mM glycine, and 20% (v/v) ethanol. The antiserum was diluted 1:1,000 with Tris-buffered saline-Tween (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 3 mM KCl, 0.05% (w/v) Tween 20) for use in PchB immunoblots, which were treated with goat anti-rabbit IgG conjugated to horseradish peroxidase (Sigma). PchB was visualized by the enhanced chemiluminescence system according to the manufacturer's instructions (Amersham Biosciences).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Purification of the PchB Enzyme-- IPL was purified from the overproducing strain P. aeruginosa ADD1976/pME3324 as described under "Experimental Procedures" and summarized in Table I. In crude extract, PchB constituted ~20% of the soluble protein. Purification by DEAE-ion exchange chromatography resulted in a 5.9-fold increase in specific activity. Hydrophobic interaction chromatography on phenyl-Sepharose and molecular sieving on Bio-Gel P100 removed some contaminants, but did not improve the specific activity (Table I). PchB protein tended to form insoluble aggregates in concentrated solution. Therefore, pooled fractions after phenyl-Sepharose chromatography were concentrated by ultrafiltration in the presence of 0.1% n-octyl-beta -D-glucopyranoside, allowing a higher recovery. Used at this concentration, n-octylglucose had no effect on IPL activity. Glycerol, which was present in buffer A, did not influence IPL activity either, in concentrations of up to 30%. PchB was eluted from the Bio-Gel column in a single symmetric peak, with a purity of >98% as judged by SDS-PAGE (Fig. 2, lane 1). The PchB polypeptide (calculated molecular mass of 11.5 kDa) migrated slightly ahead of the 14.4-kDa marker, alpha -lactalbumin (Fig. 2).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Purification of the PchB enzyme from the overproducing strain P. aeruginosa ADD1976/pME3324, based on IPL activity
Data shown are taken from a typical purification; in four independent experiments, the purification factors were reproducible ±10%.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 2.   Estimation of the molecular mass of purified PchB from P. aeruginosa by SDS-PAGE. Purified PchB (13.5 µg) was treated with 0.5 mM DTSSP and analyzed as described under "Experimental Procedures." Lane 1, PchB without DTSSP; lane 2, cross-linked PchB; lane 3, high molecular mass marker proteins, where the 36-kDa band is lactate dehydrogenase; lane 4, low molecular mass markers phosphorylase b (94 kDa), bovine serum albumin (67 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa), soybean trypsin inhibitor (20.1 kDa), and alpha -lactalbumin (14.4 kDa).

The N-terminal amino acid sequence of the PchB polypeptide (Met-Lys-Thr-Pro-Glu-Asp-X-Thr-Gly-Leu) obtained by Edman degradation matched that predicted from the DNA sequence (2) after processing of the first methionine.

Molecular Mass of Native PchB Enzyme-- Mobility of PchB in PAGE under nondenaturing conditions was similar to that of carbonic anhydrase (28.7 kDa), and a Ferguson plot indicated an apparent molecular mass of 30 ± 2 kDa. Analytical size exclusion chromatography on Sephadex G-150, Superose 12 HR, and Bio-Gel P100 gave values of ~32, 31 ± 1, and 34 ± 2 kDa, respectively, for native PchB.

PchB was cross-linked with the homobifunctional, water-soluble agent DTSSP and treated with the solubilizing buffer as described under "Experimental Procedures." After SDS-PAGE, a substantial fraction of PchB was found to migrate as a covalently linked dimer (Fig. 2, lane 2). Larger forms corresponding probably to trimers and tetramers were also seen with much lower intensities (Fig. 2, lane 2). Increasing the cross-linker concentration to 2 mM appeared to favor the dimeric form (data not shown). Treatment of cross-linked PchB with DTT converted these forms back to the monomeric subunit (data not shown). The fact that the band corresponding to the dimer was dominant after cross-linking can be interpreted in favor of a dimeric structure of native PchB. The apparent molecular mass obtained by molecular sieving would also be compatible with a trimeric PchB structure. However, CM of Methanococcus jannaschii (27), a dimeric protein whose 99-amino acid sequence is related to that of PchB (see below), showed an apparent molecular mass of 29.4 kDa in gel filtration experiments. This value is also higher than that expected for a dimeric form and was assumed to result from the nonspherical, elongated form of the dimeric species (27). In conclusion, PchB is very likely to adopt a dimeric structure in solution, but a trimeric structure cannot be totally excluded at this stage.

Catalytic Properties of PchB-- Purified PchB protein had a broad optimum of IPL activity at approximately pH 6.8 in 100 mM potassium phosphate buffer (data not shown). Preincubation of the PchB protein (1.1 µg/ml) at 37 °C for 10 min with the cation chelators EDTA, EGTA, or o-phenanthroline (each at 1 mM in assay buffer) did not affect IPL activity significantly. Addition of 10 mM MgCl2, 1 mM ZnCl2, 1 mM FeCl2, or 1 mM CaCl2 changed IPL activity by <= 20%. Thus, no metal cofactor requirement was found for PchB.

The enzyme displayed Michaelis-Menten kinetics for IPL, as derived from initial velocity data collected at isochorismate concentrations varying from 1 to 600 µM under standard assay conditions. No substrate inhibition was observed at isochorismate concentrations of up to 1,200 µM (data not shown). From Hanes plots, Vmax and Km values for isochorismate were obtained and the catalytic rate constant (kcat) was calculated per PchB monomer (11.5 kDa) (Table II).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Kinetic parameters of PchB for IPL and CM activities at 37 °C
Substrate saturation curve data were fitted to the Hanes equation ([S] v-1 = Vmax-1 [S] + Km Vmax-1). The resulting Vmax values were transformed to catalytic rate constants (kcat = Vmax Mr Eo-1), calculated per PchB monomer. The values represent the mean values of 3 independent determinations carried out as described under "Experimental Procedures." In the IPL assay, 0.54 µg of purified PchB was incubated for 15 s; in the CM assay, 5 µg of PchB was incubated for 10 min. Standard deviations of the values shown did not exceed 10%.

As sequence comparisons pointed to a possible relationship of PchB to CMs of the AroQ class, purified PchB enzyme was assayed with chorismate as the substrate. Interestingly, the enzyme displayed CM activity and showed Michaelis-Menten kinetics with chorismate as the substrate (Table II). The Km value for chorismate (150 µM) was higher than that for isochorismate (12.5 µM), whereas the kcat value calculated per monomer was lower for the Claisen rearrangement of chorismate (7.8 min-1) than that for the isochorismate-to-salicylate conversion (106 min-1), suggesting that PchB primarily functions as an IPL rather than as a CM.

Inhibitors of PchB-- Bartlett et al. (49, 50) have described an endo-oxabicyclic diacid resembling the conformation of the presumed transition state of the enzymatic rearrangement of chorismate to prephenate. This transition state analog (TSA) acts as a potent inhibitor of CM (49, 50). TSA competitively inhibited both CM and IPL activities of PchB (Fig. 3, A and B), with similar Ki values of 28 and 22 µM, respectively (Table II). This result suggests and raises the possibility that the IPL and CM activities of PchB involve a shared active site.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Competitive inhibition by TSA and chorismate of purified PchB from P. aeruginosa. A, inhibition of IPL by TSA. Panel shows double-reciprocal plot of the initial velocity v versus isochorismate concentration at different concentrations of TSA (mM): 0 (open circle ), 0.05 (), and 0.2 (triangle ). B, inhibition of CM by TSA. Panel shows double-reciprocal plot of the initial velocity v versus chorismate concentration at different concentrations of TSA (mM): 0 (open circle ), 0.01 (diamond ), and 0.05 (). C, inhibition of IPL by chorismate. Panel shows double-reciprocal plot of the initial velocity v versus isochorismate concentration at different concentrations of chorismate (mM): 0 (open circle ), 0.5 (), and 1 (triangle ). IPL and CM activities of PchB were assayed at 37 °C as described under "Experimental Procedures." The reactions were started by adding the enzyme to the prewarmed reaction mixture. Each measurement was performed at least three times.

Chorismate was a weak competitive inhibitor of the IPL reaction (Fig. 3C), with a Ki of 400 µM, as determined by a Dixon plot (Table II). The reciprocal test, i.e. potential inhibition of the CM reaction by isochorismate, could not be performed because the presence of isochorismate interfered with the standard CM assay.

Pyruvate, which is produced in the IPL reaction, did not inhibit IPL when added at 100 µM. Tryptophan, phenylalanine, tyrosine, and dihydroaeruginoate ( = hydroxyphenylthiazolinyl carboxylate, an intermediate in pyochelin biosynthesis; Fig. 1), at 100 µM each, had no effect on IPL activity, when measured with 12 µM isochorismate. At 1 mM, phenylalanine and tyrosine were weak inhibitors of IPL, causing ~30% inhibition.

PchB Has CM Activity in Vivo-- We tested whether PchB could restore a CM deficiency in vivo. As no CM-negative mutant of P. aeruginosa was available, this test was carried out with a CM-negative strain of E. coli, KA12/pKIMP-UAUC (46, 47), harboring pME6152 (pchB expressed from the inducible tac promoter).

In the presence of 1 mM IPTG, but not in the absence of the inducer, PchB was produced at high levels in E. coli as revealed by Western blotting (Fig. 4; lanes 2 and 3). Under inducing conditions, PchB represented approximately 5% of the total soluble protein in E. coli (data not shown).


View larger version (95K):
[in this window]
[in a new window]
 
Fig. 4.   Western blot analysis of PchB production in E. coli KA12/pKIMP-UAUC harboring pME6152. Crude cell extracts (2 µg of protein) were subjected to SDS-PAGE (10-20% gradient gels) followed by immunoblot analysis with anti-PchB polyclonal antibodies as described under "Experimental Procedures." Lane 1, purified PchB (0.1 µg); lane 2, crude cell extract of E. coli KA12/pKIMP-UAUC/pME6152 grown in supplemented minimal medium with IPTG induction of pchB expression; lane 3, cell extract from the same cells grown without IPTG induction.

Moreover, PchB allowed functional complementation of the CM deficiency, i.e. growth in unsupplemented minimal medium. The parent strain E. coli KA12/pKIMP-UAUC grew only when phenylalanine and tyrosine were added to the minimal medium. When this strain carried pME6152, growth occurred in minimal medium without phenylalanine and tyrosine, provided that IPTG was added (Table III). However, the doubling time, td (240 min), was approximately 3 times longer than that observed in minimal medium with added phenylalanine and tyrosine (80 min), suggesting that PchB could only partially complement the CM deficiency of the E. coli host (Table III).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Complementation of the phenylalanine and tyrosine auxotrophies of the CM-deficient strain E. coli KA12/pKIMP-UAUC by PchB from P. aeruginosa
Cells of E. coli KA12/pKIMP-UAUC (Delta (pheA-tyrA-aroF) thi-1 endA1 hsdR17 Delta (argF-lac) U169 supE44 Delta (srlR-recA) 306::Tn10/tyrA* (prephenate dehydrogenase of E. herbicola), pheC (prephenate dehydratase of P. aeruginosa)) (46, 47), without or with a pchB plasmid, were grown in minimal medium E with 0.5% glucose and 1 mM thiamine as described under "Experimental Procedures."

The minimal medium used does not contain added iron (48). Under these conditions, we expect the iron-repressible entC gene, which encodes ICS in the E. coli host, to be derepressed (52). This facilitates the rapid interconversion of the intracellular pools of chorismate and isochorismate (35, 53). Conversion of isochorismate to the thermodynamically favored salicylate by the IPL activity of PchB may therefore efficiently deplete the chorismate pool, which could result in the inability of PchB to fully complement the CM deficiency (see Fig. 1). Thus, under iron limitation, PchB would mostly function as an IPL, rather than as a CM. This scenario is consistent with the significant increase in growth rate of E. coli KA12/pKIMP-UAUC + pME6152 when 100 µM FeCl3 was added to the medium (Table III).

Isolation of an IPL-defective Mutant Form of PchB-- To improve the ability of the PchB enzyme to carry out the CM reaction in vivo, we grew E. coli KA12/pKIMP-UAUC + pME6152 for approximately 80 generations in minimal medium containing IPTG and antibiotics, but lacking tyrosine and phenylalanine. After subculturing several times, a strain showing faster growth (td = 120 min) could be isolated. The mutation causing this growth difference could be localized to the pchB gene of pME6152. When the mutated pchB gene was excised and cloned back into the same vector (pMMB67EH), the resulting plasmid pME6179 enabled strain E. coli KA12/pKIMP-UAUC to grow with the same doubling time (120 min; Table III), thus excluding the possibility that the growth advantage might have been caused by a mutation in the host or in the vector.

The mutated pchB gene of pME6179 was sequenced, and a T:A to G:C transversion was identified at nucleotide 263, leading to a replacement of isoleucine 88 with threonine. The affected position is not among those conserved between the PchB polypeptide and CMs of various origins (27). PchB showed the greatest similarity to the CM moiety (the AroQ domain) of AroQ·TyrA from Haemophilus influenzae (26.3% identity) and to the same enzyme from E. coli (24.7% identity). PchB also shows similarity (17% identity) to the CM moiety of AroQ·PheA (the P-protein) of E. coli (Fig. 5).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   Amino acid sequence alignment of PchB from P. aeruginosa with the AroQ domain of the E. coli chorismate mutase-prephenate dehydratase (AroQ·PheA) and secondary structure prediction for PchB. The protein sequences for PchB and the AroQ domain of the E. coli chorismate mutase-prephenate dehydratase (AroQ·PheA) were each analyzed with the program PHDsec (Ref. 56; www.embl-heidelberg.de/Services/sander/predictprotein/). The analysis employed a neural network, which was not trained with AroQ proteins. The predicted secondary structure is indicated for each residue as H (helical) or L (loop). N- or C-terminal regions denoted by x do not align well with the core AroQ sequences and were thus not included in the analysis. Experimental secondary structure assignments for AroQ·PheA from x-ray crystallographic data (51) are indicated for all structurally resolved residues. Bold letters highlight conserved amino acids found in the active site from the chorismate mutase moiety of the bifunctional E. coli chorismate mutase-prephenate dehydratase (AroQ·PheA), which make prominent polar interactions with the ligand TSA in the crystal structure (51). The position of the isoleucine-to-threonine mutation identified in the pchB mutant gene is highlighted with a black box. Italic numbers correspond to PchB amino acid residues (1-102).

The catalytic properties of PchBI88T were compared with the ones of wild-type PchB in cell extracts of E. coli. The apparent Km values obtained under these conditions for wild-type PchB were essentially the same as those of the purified enzyme (Tables II and III). Interestingly, PchBI88T had lost all IPL activity, but its CM activity remained unchanged (Table III). The observed accelerated growth of the host strain carrying the mutant pchB gene can thus be explained by an improved channeling of chorismate toward phenylalanine and tyrosine, which are essential products for growth in minimal medium. The fact that iron addition to the growth medium did not further reduce the doubling time (Table III) is consistent with the expectation that depletion of the intracellular chorismate pool toward salicylate is not possible anymore without the IPL function, irrespective of the induction state of entC. Thus, loss of IPL activity enabled the mutant PchB protein to carry out the CM job more effectively in the CM-deficient E. coli host.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The PchB protein, the first IPL purified from any organism, is a small enzyme. Its 101-amino acid subunit forms a homodimer, as suggested by the cross-linking experiments shown in Fig. 2. IPL catalyzes the second reaction in the pyochelin biosynthetic pathway of P. aeruginosa, following the initial PchA-dependent conversion of chorismate to isochorismate (Ref. 2 and Fig. 1). We discovered that PchB can also carry out the CM reaction (Fig. 1), in vitro and in vivo. However, the catalytic efficiency (kcat/Km) of this reaction is more than 2 orders of magnitude lower than that of the IPL reaction (Table II). Moreover, whereas the Km value of PchB for chorismate is in the range of the Michaelis constants of other typical CMs (27, 54, 55), its catalytic rate constant kcat is significantly smaller by 2-3 orders of magnitude. When PchB was overproduced at a level of approximately 5% of the total soluble protein in E. coli, its CM function (or that of the selected IPL-deficient variant PchBI88T) was apparently the growth-limiting factor when the recombinant organism was cultivated in minimal medium (Table III). It is therefore unlikely that PchB plays a significant role in aromatic amino acid biosynthesis of P. aeruginosa, even under conditions of derepression of the pchDCBA operon, i.e. when iron is limiting (22).

PchB structurally resembles CMs of the AroQ class in several respects. First, the length of the PchB sequence corresponds to the typical length of an AroQ domain, and the degree of sequence similarity of PchB with other AroQ proteins is in the range of similarities among other CMs of the AroQ family (27, 31). Second, secondary structure analysis using a neural network (56) predicts that PchB has the same all-alpha -helical structural organization as the CM moiety of AroQ·PheA from E. coli (Fig. 5). The crystal structure of the latter enzyme has been solved as a complex with TSA (51). It is an elongated dimer formed by two identical subunits, which are composed of three alpha -helices each. Two symmetrical active sites at the dimer interface bury the ligand in the core of a four-helix bundle motif. Third, the quaternary structure of PchB was found to be dimeric, too, resulting in a similar abnormal migration behavior in gel filtration experiments as described previously for the monofunctional dimeric AroQ-class CM from M. jannaschii (27). Fourth, sequence identities between PchB and AroQ proteins include amino acids that make prominent interactions with ligand in the active site of CM (Ref. 51 and Fig. 5). Specifically, of the 20 residues that are identical between PchB and E. coli AroQ·PheA (Fig. 5), 10 are among the 19 residues situated within a distance of 6 Å from any heteroatom of the TSA molecule bound in the active site of the CM domain of E. coli AroQ·PheA (Fig. 6A).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   Structure of the active site of the AroQ domain of AroQ·PheA from E. coli and the corresponding model for P. aeruginosa PchB. A, relevant section of the crystal structure of E. coli AroQ·PheA complexed with the transition state analog TSA (Protein Data Bank identification code 1ECM) (51), showing the catalytic site of the CM domain. Displayed are the 19 residues whose side chains are within 6 Å of any heteroatom of the ligand. B, homology model of PchB with bound isochorismate in a conformation suitable to fit into the presumed active site. The model was derived from the crystal structure of E. coli AroQ·PheA. Whereas the protein backbone was left unaltered, the nine E. coli AroQ·PheA-specific side chains were replaced by the corresponding PchB-specific counterparts using appropriate side chain rotamer conformations to reduce steric clashes. An Ile-88 to Thr mutation results in loss of IPL, without affecting CM activity. Carbon atoms in A and B are color-coded in turquoise (belonging to the ligand), green (fully conserved residues between E. coli AroQ·PheA and PchB), and white (nonidentical residues between AroQ·PheA and PchB).

Besides the structural similarities of the two enzymes, a series of functional resemblances points to common catalytic features of IPL and CMs of the AroQ class. First, and most importantly, PchB has CM activity. Second, TSA, which is known to mimic the transition state of the CM reaction, shows similar Ki values for both the CM and the IPL activities of PchB (Table II). Third, chorismate and isochorismate, the two alternative substrates of PchB, are distinguished only by the position of their respective hydroxyl groups (Fig. 1), leaving most of the functional groups and overall geometry of the substrates available for common binding interactions in the active site.

From the structural and functional correspondences, it is clear that there can only be a single type of active site in PchB to which both substrates must bind and which carries out the Claisen rearrangement of chorismate in addition to the conversion of isochorismate to salicylate and pyruvate. Using the three-dimensional structure of E. coli AroQ·PheA (51) complexed with TSA as a template (Fig. 6A), we built a model of the active site of PchB with bound isochorismate (Fig. 6B) to illustrate the large degree of structural conservation between the active sites of the two enzymes. It is reasonable to assume that many of the amino acids that line the binding pockets play similar roles for CM and IPL activity, and experiments addressing mechanistic questions of PchB function are in progress.3

Among the dissimilarities in the active sites of the E. coli CM and P. aeruginosa PchB are residues in the vicinity of the hydroxyl group of the substrates. For instance, in the E. coli enzyme, Glu-52, which is strongly conserved in the AroQ family (27), provides a hydrogen bond to the ligand's 4-hydroxyl group (Ref. 52 and Fig. 6A). In PchB, this residue is replaced by a valine (Val-55; Fig. 6B), which appears to be less favorable for chorismate binding but could provide a more suitable hydrophobic environment for the corresponding edge of isochorismate. The 12-fold lower affinity of PchB for chorismate versus isochorismate (Table II) may well be a consequence of this structural feature. Other differences between the active sites are apparent in the region of the 2-hydroxyl group of isochorismate. Interestingly, the residue mutated in the selected variant PchBI88T is located in this area (Fig. 6B). The exchange of isoleucine at position 88 by a threonine may prevent productive binding of isochorismate and thereby explain abolishment of all IPL activity. Because chorismate lacks a substituent at position 2, the mutation does not necessarily interfere with chorismate binding. The unchanged Km for the CM reaction of PchBI88T (Table III) is in agreement with this view.

Based on our observations, we speculate that PchB was derived from an AroQ-class CM by a gene duplication event followed by selection for efficient IPL function in the course of the evolution of the pyochelin siderophore pathway. From the fact that PchB can still use the same active site either for the IPL or for the CM reaction, it appears that the active site of the ancestral CM needed only modest alteration to be turned into an efficient IPL. Nevertheless, the required changes had a pronounced deleterious effect on the CM activity. According to this scenario, the residual CM activity of PchB would reflect no more than a remnant of its evolutionary past. If an efficient IPL can relatively easily evolve from a CM, it can be further speculated that contemporary CMs may already possess (weak) IPL activity.

It should be interesting to test established or presumed CM enzymes for the presence of this possible side activity, particularly those AroQ class members that possess a valine at the position corresponding to Glu-52 in E. coli AroQ·PheA (see alignments in Refs. 27 and 31).

    ACKNOWLEDGEMENTS

We thank M. Beyeler for help with HLPC analysis, L. Rindisbacher for raising antibodies, and P. Bartlett and E. Leistner for supplying reagents.

    FOOTNOTES

* This work was supported by Swiss National Foundation for Scientific Research Project 31-56608.99.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 41-21-692-56-31; Fax: 41-21-692-56-35; E-mail: dieter.haas@lbm.unil.ch.

Published, JBC Papers in Press, April 5, 2002, DOI 10.1074/jbc.M202410200

2 E. W. Leistner, personal communication.

3 D. Künzler and P. Kast, unpublished results.

    ABBREVIATIONS

The abbreviations used are: ICS, isochorismate synthase; AroQ·PheA, bifunctional enzyme consisting of an N-terminal chorismate mutase and a C-terminal prephenate dehydratase domain; AroQ·TyrA, as AroQ·PheA but with a C-terminal prephenate dehydrogenase domain; CM, chorismate mutase; DTSSP, 3,3'-dithiobis(sulfosuccinimidylpropionate); DTT, dithiothreitol; HPLC, high performance liquid chromatography; IPL, isochorismate pyruvate-lyase; IPTG, isopropyl-beta -D-thiogalactopyranoside; TSA, transition state analog.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ankenbauer, R. G., and Cox, C. D. (1988) J. Bacteriol. 170, 5364-5367[Abstract/Free Full Text]
2. Serino, L., Reimmann, C., Baur, H., Beyeler, M., Visca, P., and Haas, D. (1995) Mol. Gen. Genet. 249, 217-228[CrossRef][Medline] [Order article via Infotrieve]
3. Sokol, P. A., Lewis, C. J., and Dennis, J. J. (1992) J. Med. Microbiol. 36, 184-189[Abstract]
4. Saxena, B., Mayuranki, M., and Modi, V. V. (1986) J. Gen. Microbiol. 132, 2219-2224
5. Okujo, N., Saito, M., Yamamoto, S., Yoshida, T., Miyoshi, S., and Shinoda, S. (1994) Biometals 7, 109-116[Medline] [Order article via Infotrieve]
6. Gehring, A. M., DeMoll, E., Fetherstone, J. D., Mori, I., Mayhew, G. F., Blattner, F. R., and Walsh, C. T. (1998) Chem. Biol. 5, 573-586[CrossRef][Medline] [Order article via Infotrieve]
7. Adilakshmi, T., Ayling, P. D., and Ratledge, C. (2000) J. Bacteriol. 182, 264-271[Abstract/Free Full Text]
8. Hudson, A. T., and Bentley, R. (1970) Biochemistry 9, 3984-3987[Medline] [Order article via Infotrieve]
9. Hudson, A. T., and Bentley, R. (1970) Tetrahedron Lett. 24, 2077-2080
10. Marshall, B. J., and Ratledge, C. (1972) Biochim. Biophys. Acta 264, 106-116[Medline] [Order article via Infotrieve]
11. Young, I. G., Batterham, T. J., and Gibson, F. (1969) Biochim. Biophys. Acta 177, 389-400[Medline] [Order article via Infotrieve]
12. Marshall, B. J., and Ratledge, C. (1971) Biochim. Biophys. Acta 230, 643-645[Medline] [Order article via Infotrieve]
13. Daruwala, R., Bhattacharyya, D. K., Kwon, O., and Meganathan, R. (1997) J. Bacteriol. 179, 3133-3138[Abstract/Free Full Text]
14. Dahm, C., Müller, R., Schulte, G., Schmidt, K., and Leistner, E. (1998) Biochim. Biophys. Acta 1425, 377-386[Medline] [Order article via Infotrieve]
15. Rowland, B. M., and Taber, H. W. (1996) J. Bacteriol. 178, 854-861[Abstract/Free Full Text]
16. van Tegelen, L. J., Moreno, P. R., Croes, A. F., Verpoorte, R., and Wullems, G. J. (1999) Plant Physiol. 119, 705-712[Abstract/Free Full Text]
17. Essar, D. W., Eberly, L., Hadero, A., and Crawford, I. P. (1990) J. Bacteriol. 172, 884-900[Abstract/Free Full Text]
18. Chin-A-Woeng, T. F. C., Thomas-Oates, J. E., Lugtenberg, B. J. J., and Bloemberg, G. V. (2001) Mol. Plant Microbe Interact. 14, 1006-1015[Medline] [Order article via Infotrieve]
19. Cox, C. D., Rinehart, K. Jr., Moore, M. L., and Cook, J. Jr. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 4256-4260[Abstract/Free Full Text]
20. Ankenbauer, R. G., Toyokuni, T., Staley, A., Rinehart, K. L., and Cox, C. D. (1988) J. Bacteriol. 170, 5344-5351[Abstract/Free Full Text]
21. Serino, L., Reimmann, C., Visca, P., Beyeler, M., Della Chiesa, V., and Haas, D. (1997) J. Bacteriol. 179, 248-257[Abstract/Free Full Text]
22. Reimmann, C., Serino, L., Beyeler, M., and Haas, D. (1998) Microbiology 144, 3135-3148[Abstract]
23. Quadri, L. E., Keating, T. A., Patel, H. M., and Walsh, C. T. (1999) Biochemistry 38, 14941-14954[CrossRef][Medline] [Order article via Infotrieve]
24. Reimmann, C., Patel, H. M., Serino, L., Barone, M., Walsh, C. T., and Haas, D. (2001) J. Bacteriol. 183, 813-820[Abstract/Free Full Text]
25. Xia, T., Song, J., Zhao, G., Aldrich, H., and Jensen, R. A. (1993) J. Bacteriol. 175, 4729-4737[Abstract/Free Full Text]
26. Gu, W., Williams, D. S., Aldrich, H. C., Xie, G., Gabriel, D. W., and Jensen, R. A. (1997) Microb. Comp. Genomics 2, 141-158[Medline] [Order article via Infotrieve]
27. MacBeath, G., Kast, P., and Hilvert, D. (1998) Biochemistry 37, 10062-10073[CrossRef][Medline] [Order article via Infotrieve]
28. Mercado-Blanco, J., van der Drift, K. M., Olsson, P. E., Thomas-Oates, J. E., van Loon, L. C., and Bakker, P. A. (2001) J. Bacteriol. 183, 1909-1920[Abstract/Free Full Text]
29. Patel, N., Pierson, D. L., and Jensen, R. A. (1977) J. Biol. Chem. 252, 5839-5846[Free Full Text]
30. Zhao, G., Xia, T., Fischer, R. S., and Jensen, R. A. (1992) J. Biol. Chem. 267, 2487-2493[Abstract/Free Full Text]
31. Calhoun, D. H., Bonner, C. A., Gu, W., Xie, G., and Jensen, R. A. (2001) Genome Biol. 2, 0030.1-0030.16
32. Gibson, F. (1964) Biochem. J. 90, 256-261[Medline] [Order article via Infotrieve]
33. Grisostomi, C., Kast, P., Pulido, R., Huynh, J., and Hilvert, D. (1997) Bioorg. Chem. 25, 297-305[CrossRef]
34. Heide, E., and Morrison, J. F. (1978) Biochemistry 17, 1573-1580[Medline] [Order article via Infotrieve]
35. Schmidt, K., and Leistner, E. (1995) Biotechnol. Bioeng. 45, 285-291[CrossRef]
36. Rusnak, F., Liu, J., Quinn, M., Berchtold, G. A., and Walsh, C. T. (1990) Biochemistry 29, 1425-1435[CrossRef][Medline] [Order article via Infotrieve]
37. Del Sal, G., Manfioletti, G., and Schneider, C. (1988) Nucleic Acids Res. 16, 9878[Free Full Text]
38. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
39. Farinha, M. A., and Kropinski, A. M. (1990) FEMS Microbiol. Lett. 77, 221-226
40. Fürste, J. P., Pansegrau, W., Frank, R., Blöcker, H., Scholz, P., Bagdasarian, M., and Lanka, E. (1986) Gene (Amst.) 48, 119-131[CrossRef][Medline] [Order article via Infotrieve]
41. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
42. Lämmli, U. K., and Favre, M. (1973) J. Mol. Biol. 80, 575-599[CrossRef][Medline] [Order article via Infotrieve]
43. Tietz, D., and Chrambach, A. (1987) Anal. Biochem. 161, 395-411[Medline] [Order article via Infotrieve]
44. Cotton, R. G. H., and Gibson, F. (1965) Biochim. Biophys. Acta 100, 76-88[Medline] [Order article via Infotrieve]
45. Ahmad, S., and Jensen, R. A. (1988) Mol. Biol. Evol. 5, 282-297[Abstract]
46. Kast, P., Asif-Ullah, M., and Hilvert, D. (1996) Tetrahedron Lett. 37, 2691-2694[CrossRef]
47. Kast, P., Asif-Ullah, M., Jiang, N., and Hilvert, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5043-5048[Abstract/Free Full Text]
48. Vogel, H. J., and Bonner, D. M. (1956) J. Biol. Chem. 218, 97-106[Free Full Text]
49. Bartlett, P. A., Nakagawa, Y., Johnson, C. R., Reich, S. H., and Luis, A. (1988) J. Org. Chem. 53, 3195-3210[CrossRef]
50. Bartlett, P. A., and Johnson, C. R. (1985) J. Am. Chem. Soc. 107, 7792-7793[CrossRef]
51. Lee, A. Y., Karplus, P. A., Ganem, B., and Clardy, J. (1995) J. Am. Chem. Soc. 117, 3627-3628[CrossRef]
52. Kwon, O., Hudspeth, M. E., and Meganathan, R. (1996) J. Bacteriol. 178, 3252-3259[Abstract/Free Full Text]
53. Walsh, C. T., Liu, J., Rusnak, F., and Sakaitani, M. (1990) Chem. Rev. 90, 1105-1129[CrossRef]
54. Görisch, H. (1978) Biochemistry 17, 3700-3705[CrossRef][Medline] [Order article via Infotrieve]
55. Mattei, P., Kast, P., and Hilvert, D. (1999) Eur. J. Biochem. 261, 25-32[Medline] [Order article via Infotrieve]
56. Rost, B., and Sander, C. (1994) Proteins 19, 55-72[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore